Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer
Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer
复制标题
DOI：
10.1007/s13277-013-1405-8
复制
发表时间：
2014-04
期刊：
影响因子：
--
通讯作者：
F. Tas;S. Karabulut;M. Serilmez;R. Çiftçi;D. Duranyıldız
中科院分区：
文献类型：
--
作者：
F. Tas;S. Karabulut;M. Serilmez;R. Çiftçi;D. Duranyıldız
胰岛素样生长因子-1 (IGF-1) 及其主要结合蛋白 IGFBP-3 在许多肿瘤（包括卵巢癌）的细胞增殖、分化和凋亡中发挥重要作用。本研究的目的是确定上皮性卵巢癌（EOC）患者血清 IGF-1 和 IGFBP-3 水平的临床意义。共有 50 例经病理确诊的 EOC 患者纳入本研究。采用固相夹心ELISA法测定血清IGF-1和IGFBP-3水平。分析中包括二十名年龄和性别匹配的健康对照。患者的中位年龄为 56.5 岁（范围 22 至 83 岁）。大多数患者患有晚期疾病（FIGO III-IV 期；90%）。 EOC 患者和健康对照之间的基线血清 IGF-1 和 IGFBP-3 水平没有观察到显着差异（分别为 p= 0.99 和 p= 0.80）。年轻患者的血清 IGF-1 和 IGFBP-3 浓度较高（分别为 p= 0.04 和 p= 0.02）。与 CA-125 水平较高的患者相比，CA-125 水平正常的患者血清 IGFBP-3 浓度较高 (p= 0.008)。然而，没有发现其他临床变量，包括组织学、肿瘤分级、疾病阶段和化疗反应与血清 IGF 测定相关（p> 0.05）。血清IGF-1和IGFBP-3水平之间存在显着相关趋势(rs= 0.212,p= 0.07)。血清 IGF-1 水平升高的患者比水平较低的患者具有良好的无进展生存期和总生存期（分别为 p= 0.04 和 p= 0.03）。然而，血清 IGFBP-3 浓度被发现对两种生存没有预后作用（分别为 p= 0.12 和 p= 0.26）。总之，血清 IGF-1 水平升高与 EOC 患者良好的无进展生存期和总生存期相关。
Insulin-like growth factor-1 (IGF-1) and its primary binding protein IGFBP-3 play an important role in cellular proliferation, differentiation, and apoptosis in many tumors, including ovarian cancer. The objective of this study was to determine the clinical significance of the serum levels of IGF-1 and IGFBP-3 in epithelial ovarian cancer (EOC) patients. A total of 50 patients with a pathologically confirmed diagnosis of EOC were enrolled into this study. Serum IGF-1 and IGFBP-3 levels were determined by the solid-phase sandwich ELISA method. Twenty age- and sex-matched healthy controls were included in the analysis. Median age of patients was 56.5 years old (range 22 to 83 years). Majority of the patients had advanced disease (FIGO stage III–IV; 90 %). No significant difference was observed in baseline serum IGF-1 and IGFBP-3 levels between EOC patients and healthy controls (p= 0.99 andp= 0.80, respectively). The young patients had higher serum IGF-1 and IGFBP-3 concentrations (p= 0.04 andp= 0.02, respectively). Patients with normal CA-125 levels had higher serum IGFBP-3 concentrations compared with those with higher CA-125 levels (p= 0.008). However, no other clinical variables including histology, tumor grade, stage of disease, and response to chemotherapy were found to be correlated with serum IGF assays (p> 0.05). A trend to significant relationship was found between the serum levels of IGF-1 and IGFBP-3 (rs= 0.212,p= 0.07). The patients with elevated serum IGF-1 levels had favorable progression-free and overall survivals than those with lower levels (p= 0.04 andp= 0.03, respectively). However, serum IGFBP-3 concentrations were found to have no prognostic role for both survivals (p= 0.12 andp= 0.26, respectively). In conclusion, elevated serum level of IGF-1 is associated with favorable progression-free and overall survivals in EOC patients.